Company profile

Ticker
DVAX
Exchange
Website
CEO
Ryan Spencer
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
330728374

DVAX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Nov 20
24 Nov 20
31 Dec 20

News

Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
23 Sep 20 Peter R. Paradiso Stock Option Common Stock Grant Aquire A No 4.53 50,000 226.5K 50,000
17 Jul 20 Janssen Robert Common Stock Sell Dispose S Yes 11.09 50,000 554.5K 127,266
17 Jul 20 Eastland Julia Marie Stock Option Common Stock Grant Aquire A No 11.37 50,000 568.5K 50,000
80.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 166 153 +8.5%
Opened positions 41 51 -19.6%
Closed positions 28 13 +115.4%
Increased positions 50 51 -2.0%
Reduced positions 40 25 +60.0%
13F shares
Current Prev Q Change
Total value 877.07M 15.44B -94.3%
Total shares 88.16M 80.68M +9.3%
Total puts 842.2K 575K +46.5%
Total calls 797.4K 1.56M -48.9%
Total put/call ratio 1.1 0.4 +186.6%
Largest owners
Shares Value Change
STT State Street 11.6M $50.13M +129.4%
FHI Federated Hermes 10.95M $47.29M -2.0%
Bain Capital Life Sciences Investors 10.9M $47.07M 0.0%
BLK BlackRock 8.16M $35.27M +17.1%
Vanguard 5.21M $22.5M +4.4%
Chicago Capital 3.93M $16.98M -19.9%
Partner Fund Management 2.94M $12.69M +156.8%
Redmile 2.55M $11.01M -49.7%
AMP Ameriprise Financial 2.11M $9.08M +72.5%
Citadel Advisors 2.1M $9.06M -28.4%
Largest transactions
Shares Bought/sold Change
STT State Street 11.6M +6.54M +129.4%
Redmile 2.55M -2.51M -49.7%
Partner Fund Management 2.94M +1.79M +156.8%
Ubs Global Asset Management Americas 78.46K -1.57M -95.2%
BLK BlackRock 8.16M +1.19M +17.1%
Millennium Management 1.12M +1.12M NEW
Chicago Capital 3.93M -974.17K -19.9%
AMP Ameriprise Financial 2.11M +885.05K +72.5%
Two Sigma Investments 1.3M +868.61K +202.4%
Citadel Advisors 2.1M -832.86K -28.4%

Financial report summary

?
Competition
PfizerAmgenGenentechVBI VaccinesCelgeneIdera PharmaceuticalsMedimmuneRocheNovartisAgenus
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: BMGF, book, broader, compliant, compound, deferred, Foundation, fourth, GASC, invoice, Melinda, objective, October, outpace, output, promptly, publicly, recoverable, reliant, replenished, scale, Scotland, seasonal, twelve, Valneva
Removed: paragraph, preceding

Patents

GRANT
Utility
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
25 Aug 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
GRANT
Utility
Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
28 Jul 20
The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker.
APP
Utility
Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds and Uses Thereof
25 Jun 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
GRANT
Utility
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
14 Apr 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
GRANT
Utility
Branched chimeric compounds, and methods of use thereof
4 Feb 20
The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides.